Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment

Novo Nordisk shares surged up to 5% following the accelerated US FDA approval of its weight-loss drug Wegovy for metabolic dysfunction-associated steatohepatitis (MASH), marking the first GLP-1 class therapy cleared for the progressive liver condition. This positive news comes after the company recently shed over one-third of its market value due to a profit warning. While opening a significant new market opportunity, analysts note that rival Eli Lilly's promising MASH data with tirzepatide suggests Novo's market exclusivity may be transitional, intensifying the competitive landscape in the broader GLP-1 drug sector.

Analysis

Novo Nordisk shares (NOVOb.CO) rallied as much as 5% following the U.S. Food and Drug Administration's accelerated approval for its drug Wegovy to treat metabolic dysfunction-associated steatohepatitis (MASH). This regulatory milestone is significant as it makes Wegovy the first GLP-1 class therapy approved for this progressive liver condition, which affects an estimated 5% of U.S. adults, opening a substantial new market. The positive news provides a crucial uplift for the company, which recently saw its market value decline by over one-third ($70 billion) after issuing a profit warning. However, the first-mover advantage appears tenuous. Key competitor Eli Lilly (LLY.N) has already published encouraging mid-stage trial data for its own treatment, tirzepatide, in MASH. Echoing this competitive threat, a Nordnet analyst noted that Novo's market exclusivity is expected to be a "transitional phase," underscoring the intense and ongoing rivalry in the broader obesity and related-ailment drug markets.

Key Decisions for Investors

• Investors should weigh this positive regulatory catalyst against the stock's recent severe underperformance, as the MASH approval could signal a potential recovery point or a temporary reprieve from broader competitive pressures.
• Monitor Eli Lilly's clinical progress and regulatory timeline for tirzepatide in MASH, as its market entry will be a critical determinant of Novo Nordisk's long-term market share and pricing power in this new indication.
• Consider the MASH approval as a diversification of Wegovy's label, but remain cautious about the overarching concerns regarding the company losing ground to Eli Lilly and copycat drugs, which have contributed to the stock losing over two-thirds of its value since last June.